MARKET

RVNC

RVNC

Revance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.84
+1.35
+5.10%
After Hours: 27.07 -0.77 -2.77% 16:26 09/17 EDT
OPEN
26.51
PREV CLOSE
26.49
HIGH
27.92
LOW
26.26
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
33.83
52 WEEK LOW
22.89
MARKET CAP
2.00B
P/E (TTM)
-5.8932
1D
5D
1M
3M
1Y
5Y
BRIEF-Revance To Showcase Data From Phase 3 Trial Of Daxibotulinumtoxina For Injection At International Parkinson And Movement Disorder Society Virtual Congress 2021
reuters.com · 1d ago
Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021
Revance Therapeutics, Inc. (Nasdaq: RVNC) a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it will present an ePoster with a video poster presentation by Dr. Joseph Jankovic at the International Parkin...
Business Wire · 1d ago
Those who invested in Revance Therapeutics (NASDAQ:RVNC) five years ago are up 62%
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...
Simply Wall St. · 4d ago
Revance Presents Data on the RHA(R) Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting
--- Supports Revance's commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations -
Business Wire · 09/10 12:00
Revance to Participate in the Wells Fargo Securities Healthcare Conference
NASHVILLE, Tenn., September 02, 2021--Revance to Participate in the Wells Fargo Securities Healthcare Conference
Business Wire · 09/02 12:00
BRIEF-Revance Publishes Results On Static Glabellar Lines Treatment
reuters.com · 09/01 12:30
Revance Highlights Publication Of Results On Static Glabellar Lines With Repeated Treatment Of DaxibotulinumtoxinA For Injection From The SAKURA Clinical Program In Dermatologic Surgery
- Post-hoc analysis demonstrates sustained improvement of static glabellar lines with repeated treatment of DaxibotulinumtoxinA for Injection - Results suggest that the extended duration of therapeutic benefit
 Post-hoc analysis demonstrates sustained improvement of static glabellar lines with repeated treatment of DaxibotulinumtoxinA for Injection - Results suggest that the extended duration of therapeutic benefit · 09/01 12:05
Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
NASHVILLE, Tenn., September 01, 2021--Revance Publishes SAKURA Results on Static Glabellar Lines with Repeated Treatment of DaxibotulinumtoxinA for Injection in Dermatologic Surgery
Business Wire · 09/01 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RVNC. Analyze the recent business situations of Revance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RVNC stock price target is 39.78 with a high estimate of 55.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 208
Institutional Holdings: 61.50M
% Owned: 85.63%
Shares Outstanding: 71.83M
TypeInstitutionsShares
Increased
54
2.20M
New
22
882.90K
Decreased
44
3.06M
Sold Out
13
755.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Angus Russell
President/Chief Executive Officer/Director
Mark Foley
Chief Financial Officer
Tobin Schilke
Corporate Executive/Director
Aubrey Rankin
Chief Operating Officer
Abhay Joshi
Senior Vice President/General Counsel/Secretary
Dwight Moxie
Other
Dustin Sjuts
Independent Director
Jill Beraud
Independent Director
Julian Gangolli
Independent Director
Carey Kolaja
Independent Director
Chris Nolet
Independent Director
Philip Vickers
Independent Director
Olivia Ware
No Data
About RVNC
Revance Therapeutics, Inc. is a biotechnology company that is focused on aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines, and crow’s feet, as well as in two therapeutic indications cervical dystonia and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for the correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription, and loyalty digital services.

Webull offers kinds of Revance Therapeutics Inc stock information, including NASDAQ:RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.